TrialNCT06701396Phase 3Recruiting
Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant
Study sponsor: Vanda Pharmaceuticals
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Primary completion2025-06-30Estimated
Enrollment · participants60Estimated
Source updated2024-11-22Last update listed in the registry record
Version history
Changes to this trial
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.